Somatostatin Receptor Subtype Expression in Human Thyroid Tumours

.

[1]  A. Scarpa,et al.  Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas , 2008, Neuroendocrinology.

[2]  C. Schwarzer,et al.  Evidence for Somatostatin receptor 2 in thyroid tissue , 2007, Regulatory Peptides.

[3]  Eva Forssell-Aronsson,et al.  111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[5]  Eva Forssell-Aronsson,et al.  Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. , 1998, British Journal of Cancer.

[6]  Y. Patel.  Molecular pharmacology of somatostatin receptor subtypes , 1997, Journal of endocrinological investigation.

[7]  K. Ain,et al.  Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. , 1997, The Journal of clinical endocrinology and metabolism.

[8]  H. Niznik,et al.  The somatostatin receptor family. , 1995, Life sciences.

[9]  L. Kvols,et al.  Somatostatin receptors in malignant tissues , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  H. Bruining,et al.  Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. , 1990, The Journal of clinical endocrinology and metabolism.

[11]  F. Raulf,et al.  Somatostatin analogs for diagnosis and treatment of cancer. , 1993, Pharmacology & therapeutics.